Semaglutide (Ozempic/Wegovy) reduced major cardiovascular events by 20% in the landmark SELECT trial (2023) in non-diabetic obese patients, establishing GLP-1 receptor agonists as a cardiovascular drug class beyond glycemic control.
Research summaries are AI-generated from open-access peer-reviewed literature (PubMed Central, Cochrane, AHA/ACC). Content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.